As North Korea battles its first known COVID outbreak, a lack of storage, chronic power shortages and inadequately trained medical staff pose acute challenges to inoculating its 25 million people - even with outside help, analysts said.
North Korea has not responded to offers of aid from South Korea and international vaccine-sharing programmes, but prefers U.S.-made Moderna and Pfizer over China's Sinovac or British-Swedish Astrazeneca shots, according to South Korean officials.
